Terapia Génica del Cáncer
TGC
![Foto de Terapia Génica del Cáncer](/img/uploaded/2638e8f8b318fa3e2dc194b3248c709e.jpg)
![Foto de Dana–Farber Cancer Institute](/img/noimage_org.png)
Dana–Farber Cancer Institute
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (2)
2022
-
Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential
British Journal of Cancer, Vol. 126, Núm. 11, pp. 1595-1603
2020
-
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
Journal of Thoracic Oncology, Vol. 15, Núm. 4, pp. 618-627